Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50

Recruiting now

Conditions studied: Multiple Sclerosis (MS)

In brief

The objective of this study is to evaluate the risk of inflammatory disease activity by retrospectively comparing two therapeutic strategies (escalation group and induction group). The investigators also aim to identify factors associated with inflammatory relapse and treatment-related complications.

Key facts

Study ID

NCT07313462

Run by

University Hospital, Strasbourg, France

People needed

830

Starts

2025-02-07

Expected to finish

2026-02-01

Last updated by the study team

2026-01-02

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with RRMS onset after age 50
• Patients who started their first disease-modifying therapy within 2 years of the first symptoms
• Patients Treated with moderately effective disease-modifying antirheumatic drugs (DMARDs) (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon)
• Patient treated with highly effective DMARDs (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine)

You may not qualify if…

• Patients with early progressive MS

Where it is running

• Centre d'Investigation Clinique - CHU de Strasbourg - France — Strasbourg, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.